ICON Announces Service Agreement with Pfizer
10 Junho 2016 - 7:00AM
Business Wire
ICON plc, (NASDAQ: ICLR), a global provider of
outsourced development services to the pharmaceutical,
biotechnology and medical device industries, today announced it has
signed a three-year agreement with Pfizer Inc. (NYSE:PFE). Under
the terms of the agreement, Pfizer has the right to extend the term
for up to an additional two years. Financial details of the
agreement were not disclosed.
The new agreement builds on the companies’ existing
relationship, under which ICON provides global expertise in the
planning, execution, management and conduct of clinical trials.
Ciaran Murray, ICON’s CEO, commented: "The progression of our
relationship with Pfizer is a recognition of ICON’s capabilities in
supporting drug development efforts. We look forward to continuing
our relationship with Pfizer to help advance its development
pipeline and innovation in the drug development process.”
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 89 locations in 37 countries and has approximately
12,200 employees. Further information is available at
www.iconplc.com.
ICON/ICLR-F
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160610005206/en/
ICONInvestor Relations1-888-381-7923orBrendan BrennanChief
Financial Officer+ 353 –1-291-2000orSimon HolmesEVP Investor
Relations and Corporate Development+ 353 –1-291-2000
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024